🇺🇸 FDA
Patent

US 9220692

Methods of reducing symptoms in subjects using single dosage forms with tapering release rates

granted A61KA61K31/00A61K31/137

Quick answer

US patent 9220692 (Methods of reducing symptoms in subjects using single dosage forms with tapering release rates) held by TEVA WOMEN'S HEALTH, INC. expires Mon Dec 24 2035 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
TEVA WOMEN'S HEALTH, INC.
Grant date
Tue Dec 29 2015 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Dec 24 2035 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
19
CPC classes
A61K, A61K31/00, A61K31/137, A61K31/465, A61K31/515